Methods of treating viral infections

• US 8,993,542 B2
• Filed: 01/23/2009
• Issued: 03/31/2015
• Est. Priority Date: 01/25/2008
• Status: Active Grant

• Current Assignee: Chimerix Incorporated
• Original Assignee: Chimerix Incorporated
• Inventors: Lanier, Ernest Randall, Almond, Merrick R., Painter, George R.
• Primary Examiner(s): Wang, Shengjun
• Application Number:
  US12/864,431
• Publication Number:
  US 20110021464A1
• Time in Patent Office: 2,258 Days
• Field of Search: 514/80, 514/254, 514/274
• US Class Current: 514/80
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/706 containing six-membered rings with nitrogen as a ring hetero atom
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides methods of treating human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, including administering a compound described in the invention in an amount effective treat the HIV and/or HBV infection and at least substantially inhibit the development of resistance to said antiviral compounds in the subject. Pharmaceutical compositions are also provided.

Claims

1. A method of treating a subject for human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, wherein the subject has not been previously administered an antiviral active agent for said HIV or HBV infection, the method comprising:

concurrently administering to the subject an antiviral compound of the Formula;

2. The method of claim 1, wherein said subject is immunocompromised.

3. The method of claim 1, wherein said virus is HBV and not HIV.

4. The method of claim 1, wherein said subject is infected with both HBV and HIV, and said antiviral compound is administered in an amount effective to treat both said HBV and HIV.

5. The method of claim 1, wherein said subject is in utero and said antiviral compound is administered to a mother carrying said subject in utero.

6. A method of treating a subject for human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, wherein said subject has developed resistance or a toxic response to at least one other antiviral compound in response to prior administration of said at least one other antiviral compound to said subject for said HIV or HBV infection, the method comprising:

concurrently administering to said subject an antiviral compound of the Formula;

7. The method of claim 6, wherein the virus is HBV and not HIV.

8. The method of claim 6, wherein said subject is infected with both HBV and HIV, and said antiviral compound is administered in an amount effective to treat both said HBV and HIV.

9. The method of claim 6, wherein said subject is in utero and said antiviral compound is administered to a mother carrying said subject in utero.

10. A pharmaceutical composition comprising:

(a) an antiviral compound of the Formula;

11. A method of treating a subject for human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, wherein the subject has not been previously administered an antiviral active agent for said HIV or HBV infection, the method comprising:

administering to the subject an antiviral compound of the formula;

12. A method of treating a subject for human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, wherein the subject has not been previously administered an antiviral active agent for said HIV or HBV infection, the method comprising:

administering to the subject zalcitabine, followed by administering to the subject an antiviral compound of the formula;

13. A method of treating a subject for human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, wherein said subject has developed resistance or a toxic response to at least one other antiviral compound in response to prior administration of said at least one other antiviral compound to said subject for said HIV or HBV infection, the method comprising:

administering to said subject an antiviral compound of the Formula;

14. A method of treating a subject for human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, wherein said subject has developed resistance or a toxic response to at least one other antiviral compound in response to prior administration of said at least one other antiviral compound to said subject for said HIV or HBV infection, the method comprising:

administering to the subject zalcitabine, followed by administering to the subject an antiviral compound of the formula;